rosiglitazone has been researched along with Coronary Disease in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 19 (86.36) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alméras, N; Bertrand, OF; Brassard, P; Costerousse, O; Després, JP; Grenier, A; Poirier, EP | 1 |
| Edin, ML; Hanif, A; Morisseau, C; Nayeem, MA; Zeldin, DC | 1 |
| Besler, C; Doerries, C; Giannotti, G; Landmesser, U; Lüscher, TF | 1 |
| Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS | 1 |
| Amoruso, A; Bardelli, C; Brunelleschi, S; Ferrero, V; Fresu, LG; Gunella, G; Ribichini, F; Rondano, E; Vassanelli, C | 1 |
| Arnold Chan, K; Koro, C; Landon, J; McAfee, AT; Ziyadeh, N | 1 |
| Cowan, D; Kaski, JC; Sidhu, JS; Tooze, JA | 1 |
| Cowan, D; Kaski, JC; Sidhu, JS | 1 |
| Dawood, T; Honisett, SY; Kingwell, BA; Komesaroff, PA; Stojanovska, L; Sudhir, K | 1 |
| Guan, Y; Jin, N; Mao, J; Wang, G; Wang, X; Wei, J | 1 |
| Airaksinen, KE; Ball, E; Borra, R; Härkönen, R; Iozzo, P; Knuuti, J; Lautamäki, R; Luotolahti, M; Nuutila, P; Seppänen, M; Stewart, M; Toikka, J | 1 |
| Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R | 1 |
| Beaser, RS; Levy, P | 1 |
| Abdel-Latif, A; AlMahameed, A; Bhatt, DL; Blankenship, JC; Brennan, D; Chew, DP; Corbelli, JC; Eres, A; Gilchrist, IC; Grines, C; Hazen, SL; Leesar, M; McErlean, E; Mukherjee, D; Resar, JR; Steinhubl, S; Tan, WA; Tang, HW; Tang, WH; Topol, EJ | 1 |
| Ball, SG; Mughal, RS; O'Regan, DJ; Porter, KE; Turner, NA; Warburton, P | 1 |
| Jin, N; Mao, J; Wang, G; Wang, X; Yu, J; Zhang, F | 1 |
| Koro, C; McAfee, AT; Walker, AM | 1 |
| Koro, CE; Landon, J; Walker, AM | 1 |
| Chinetti, G; Delerive, P; Fadel, A; Fruchart, JC; Habib, A; Koenig, W; Lebret, M; Maclouf, J; Merval, R; Najib, J; Staels, B; Tedgui, A; Torra, IP | 1 |
| Diamond, RH; Forman, LM; Simmons, DA | 1 |
| Boscia, J; Everitt, D; Freid, J | 1 |
| Blumenthal, RS; Nass, CM | 1 |
2 review(s) available for rosiglitazone and Coronary Disease
| Article | Year |
|---|---|
Pharmacological approaches to improve endothelial repair mechanisms.
Topics: AC133 Antigen; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, CD; Antigens, CD34; Atherosclerosis; Benzopyrans; Carbazoles; Cardiovascular Diseases; Carvedilol; Cell Differentiation; Coronary Disease; Endothelium, Vascular; Erythropoietin; Ethanolamines; Glycoproteins; Hematopoietic Stem Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Nebivolol; Neovascularization, Physiologic; Oxidative Stress; Peptides; PPAR gamma; Propanolamines; Receptors, Angiotensin; Regeneration; Risk Factors; Rosiglitazone; Stem Cells; Thiazolidinediones; Vasodilator Agents | 2008 |
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
8 trial(s) available for rosiglitazone and Coronary Disease
| Article | Year |
|---|---|
Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes.
Topics: Adiposity; Adult; Aged; Body Mass Index; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed; Waist Circumference | 2016 |
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.
Topics: Blood Platelets; Coronary Disease; Diabetes Complications; Double-Blind Method; Female; Humans; Insulin Resistance; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Count; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
Topics: Aged; Brachial Artery; C-Reactive Protein; Coronary Disease; Endothelium, Vascular; Humans; Intercellular Adhesion Molecule-1; Male; Middle Aged; Prospective Studies; Regional Blood Flow; Rosiglitazone; Thiazolidinediones; Vascular Cell Adhesion Molecule-1; Vasodilation; Vasodilator Agents; von Willebrand Factor | 2004 |
Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone.
Topics: Aged; Blood Pressure; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Estradiol; Female; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Postmenopause; Progesterone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; C-Reactive Protein; Chemokine CCL2; Chemokines; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Inflammation; Lipopolysaccharides; Male; Middle Aged; Monocytes; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.
Topics: Aged; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Myocardium; Rosiglitazone; Thiazolidinediones | 2005 |
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Diseases; Coronary Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arteries; Blood Flow Velocity; C-Reactive Protein; Chemokine CCL2; Coronary Disease; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
12 other study(ies) available for rosiglitazone and Coronary Disease
| Article | Year |
|---|---|
Effect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPARγ.
Topics: Animals; Chromatography, Liquid; Coronary Disease; Epoxide Hydrolases; Hyperemia; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxylipins; PPAR gamma; Rosiglitazone; Tandem Mass Spectrometry; Thiazolidinediones | 2016 |
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Smoking; Sulfonylurea Compounds; Survival Analysis; Survivors; Thiazolidinediones | 2009 |
Tobacco smoke affects expression of peroxisome proliferator-activated receptor-gamma in monocyte/macrophages of patients with coronary heart disease.
Topics: Actins; Aged; Cell Differentiation; Coronary Disease; Cytokines; Female; Humans; Hypoglycemic Agents; Ligands; Macrophages; Male; Middle Aged; Monocytes; NF-kappa B; Nicotiana; PPAR gamma; Rosiglitazone; Smoke; Thiazolidinediones | 2009 |
The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Topics: Adult; Aged; Cohort Studies; Coronary Disease; Death, Sudden; Female; Follow-Up Studies; Heart Rate; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Outcome; United States | 2009 |
Metabolic syndrome: a work in progress, but a useful construct.
Topics: Abdominal Fat; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; Models, Biological; Obesity; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones.
Topics: Analysis of Variance; Antibodies, Monoclonal; Cells, Cultured; Chromans; Coronary Disease; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1alpha; Interleukin-1beta; Interleukin-6; Interleukins; Myocytes, Cardiac; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Simvastatin; Stimulation, Chemical; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2007 |
Studies of diabetes, thiazolidinediones, and coronary heart disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Hospitalization; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Topics: Cohort Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Outcome Assessment, Health Care; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Humans; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1; Interleukin-6; Isoenzymes; Membrane Proteins; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 1998 |
Hepatic failure in a patient taking rosiglitazone.
Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Male; Monitoring, Physiologic; Pravastatin; Rosiglitazone; Thiazoles; Thiazolidinediones; Verapamil | 2000 |
Rosiglitazone and hepatic failure.
Topics: Coronary Disease; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |